Sergio Fava

503 total citations
10 papers, 165 citations indexed

About

Sergio Fava is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Sergio Fava has authored 10 papers receiving a total of 165 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Pathology and Forensic Medicine and 2 papers in Genetics. Recurrent topics in Sergio Fava's work include Lymphoma Diagnosis and Treatment (4 papers), Neutropenia and Cancer Infections (3 papers) and Viral-associated cancers and disorders (2 papers). Sergio Fava is often cited by papers focused on Lymphoma Diagnosis and Treatment (4 papers), Neutropenia and Cancer Infections (3 papers) and Viral-associated cancers and disorders (2 papers). Sergio Fava collaborates with scholars based in Italy and Switzerland. Sergio Fava's co-authors include Graziella Pinotti, Ercole Brusamolino, Luigi Rigacci, G. Pagnucco, Livio Gargantini, Enrica Morra, Chiara Rusconi, Mario Lazzarino, Lilj Uziel and Cristiana Pascutto and has published in prestigious journals such as Journal of Clinical Oncology, The Oncologist and Chemotherapy.

In The Last Decade

Sergio Fava

9 papers receiving 161 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sergio Fava Italy 5 77 75 46 37 33 10 165
M. Simon Germany 6 61 0.8× 64 0.9× 25 0.5× 34 0.9× 32 1.0× 19 202
Adi Broyde Israel 3 91 1.2× 62 0.8× 34 0.7× 26 0.7× 21 0.6× 8 159
Richard Chasty United Kingdom 6 133 1.7× 68 0.9× 54 1.2× 11 0.3× 32 1.0× 13 249
Simona Sammassimo Italy 7 55 0.7× 79 1.1× 31 0.7× 12 0.3× 19 0.6× 26 158
R. Mozzana Italy 7 84 1.1× 54 0.7× 68 1.5× 14 0.4× 18 0.5× 24 195
Taizo A. Nakano United States 9 38 0.5× 69 0.9× 20 0.4× 31 0.8× 19 0.6× 30 246
Lourdes Martín‐Martín Spain 6 86 1.1× 106 1.4× 45 1.0× 58 1.6× 22 0.7× 6 238
William Murray‐Brown Australia 6 44 0.6× 64 0.9× 30 0.7× 6 0.2× 10 0.3× 8 221
Pallavi Galera United States 6 51 0.7× 75 1.0× 33 0.7× 9 0.2× 19 0.6× 13 153
Alain Mina United States 9 26 0.3× 70 0.9× 31 0.7× 9 0.2× 49 1.5× 31 201

Countries citing papers authored by Sergio Fava

Since Specialization
Citations

This map shows the geographic impact of Sergio Fava's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sergio Fava with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sergio Fava more than expected).

Fields of papers citing papers by Sergio Fava

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sergio Fava. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sergio Fava. The network helps show where Sergio Fava may publish in the future.

Co-authorship network of co-authors of Sergio Fava

This figure shows the co-authorship network connecting the top 25 collaborators of Sergio Fava. A scholar is included among the top collaborators of Sergio Fava based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sergio Fava. Sergio Fava is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Akaza, Hideyuki, Giuseppe Procopio, Gaetano Facchini, et al.. (2018). Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry. Journal of Global Oncology. 4(4). 1–12. 21 indexed citations
2.
3.
Roila, Fausto, Enzo Ballatori, Benedetta Ruggeri, et al.. (2014). Aprepitant versus metoclopramide, both combined with dexamethasone, for preventing cisplatin-induced delayed emesis: A randomized, double-blind study.. Journal of Clinical Oncology. 32(15_suppl). 9503–9503. 3 indexed citations
4.
Fagnani, Daniele, V. Filipazzi, Marco Danova, et al.. (2014). Granulocyte Colony-stimulating Factors Used in Clinical Practice: PoloNord Registry-Based Cohort Italian Study. Tumori Journal. 100(5). 491–498. 12 indexed citations
5.
Fava, Sergio. (2013). Environmental Apocalypse in Science and Art. 4 indexed citations
6.
Ferreri, Andrés J.M., Giada Licata, Marco Foppoli, et al.. (2011). Clinical Relevance of the Dose of Cytarabine in the Upfront Treatment of Primary CNS Lymphomas with Methotrexate-Cytarabine Combination. The Oncologist. 16(3). 336–341. 24 indexed citations
7.
Brusamolino, Ercole, Chiara Rusconi, Livio Gargantini, et al.. (2006). Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity.. PubMed. 91(4). 496–502. 83 indexed citations
9.
Pogliani, Enrico Maria, Giorgio La Nasa, Luca Baldini, et al.. (1996). EBVD and alternating MOPP/EBVD with or without localized field radiotherapy in advanced or unfavorably presenting Hodgkin's disease.. PubMed. 81(1). 8–14. 2 indexed citations
10.
Luoni, M, Paolo Declich, Alberto De Paoli, et al.. (1995). Bone Marrow Biopsy for the Staging of Non-Hodgkin's Lymphoma: Bilateral or Unilateral Trephine Biopsy?. Tumori Journal. 81(6). 410–413. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026